The main findings of this study are that CML treatment resulted in: i) significantupregulation of the NF-κB gene expression in DN and T2DM; and ii)significantly higher levels of TNF production in DN and T2DM. This evidence concerns the gene TNF and chronic myelogenous leukemia, BCR-ABL1 positive.